相关实验视频

Updated: Jan 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

通过虚拟查,分子动力学模拟和MM/GBSA分析,基于结构的新型TAOK3抑制剂的发现

Ali M Alaseem¹, Glowi Alasiri², Mohamed M El-Wekil³

¹Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.

Journal of molecular graphics & modelling

|January 16, 2026

概括

研究人员确定Z1化合物是癌症治疗的有前途的TAOK3抑制剂. 这一发现为开发向抗癌药物提供了潜在的新化合物,显示出强大的结合亲和力和有利的类似药物的特性.

科学领域:

在瘤学瘤学.
药用化学医学化学
计算生物学计算生物学

背景情况:

癌症仍然是全球主要的死亡原因.
线素激活蛋白激酶 (MAPK) 途径对癌症进展和耐药性至关重要.
陶氏激酶3 (TAOK3) 是MAPK通路中的瘤调节剂,也是潜在的治疗点,但缺乏临床抑制剂.

研究的目的:

通过基于结构的虚拟查来识别TAOK3的新型小分子抑制剂.
评估潜在的TAOK3抑制剂的结合亲和力,类似药物的特性和稳定性.

主要方法:

基于结构的虚拟选10,000个类似的化合物对TAOK3.
分子对接以确定排名最高的候选人.
用于药物相似性评估的ADMET分析.
分子动力学模拟和MM/GBSA计算以确认结合稳定性和亲和力.

主要成果:

化合物Z1 (ZINC ID: 77585305) 呈现出最高的结合亲和力 (ΔG = -8.42 kcal/mol),超过已知的抑制剂.
Z1表现出有利的ADMET特性,表明胃肠道吸收良好,毒性低.
分子动力学和自由能量计算证实了Z1与TAOK3.3的稳定和强大的结合.

结论:

化合物Z1是一种非常有前途的TAOK3抑制剂,具有出色的结合特性和类似药物的特性.
Z1代表了进一步实验研究和针对TAOK3途径的抗癌药物开发的潜在主要化合物.

关键词:

发现抗癌药物的发现.这就是MAPKK.在MM/GBSA中使用.分子动力学模拟模型这是一种TAOK3抑制剂.虚拟选是一个虚拟的选.

更多相关视频

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...